Total Payments
$7,714
2024 Payments
$362.34
Companies
44
Transactions
460
Medicare Patients
3,537
Medicare Billing
$416,449
Payment Breakdown by Category
Food & Beverage$7,500 (97.2%)
Education$214.62 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,500 | 451 | 97.2% |
| Education | $214.62 | 9 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $1,045 | 58 | $0 (2024) |
| Merck Sharp & Dohme LLC | $702.31 | 46 | $0 (2023) |
| Corcept Therapeutics | $680.47 | 32 | $0 (2024) |
| Gilead Sciences, Inc. | $640.03 | 33 | $0 (2023) |
| ViiV Healthcare Company | $637.83 | 48 | $0 (2021) |
| Novo Nordisk Inc | $630.29 | 43 | $0 (2024) |
| ABBVIE INC. | $622.62 | 48 | $0 (2023) |
| Xeris Pharmaceuticals, Inc. | $264.58 | 13 | $0 (2024) |
| Insulet Corporation | $174.99 | 10 | $0 (2022) |
| Amneal Pharmaceuticals LLC | $174.97 | 11 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $362.34 | 16 | Lilly USA, LLC ($106.71) |
| 2023 | $506.06 | 23 | Lilly USA, LLC ($175.74) |
| 2022 | $612.56 | 31 | Lilly USA, LLC ($101.67) |
| 2021 | $1,349 | 77 | Lilly USA, LLC ($234.71) |
| 2020 | $848.61 | 47 | Corcept Therapeutics ($169.01) |
| 2019 | $993.88 | 57 | Corcept Therapeutics ($163.58) |
| 2018 | $1,258 | 81 | ViiV Healthcare Company ($193.28) |
| 2017 | $1,783 | 128 | Novo Nordisk Inc ($263.78) |
All Payment Transactions
460 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Acella Pharmaceuticals, LLC | NP Thyroid 60 (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: Hyperthyroidism | ||||||
| 10/28/2024 | RECORDATI_RARE_DISEASES_INC. | SIGNIFOR LAR (Drug), ISTURISA | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: ENDOCRINE AGENT | ||||||
| 10/25/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $32.31 | General |
| Category: Endocrinology | ||||||
| 10/24/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Biological | ||||||
| 10/02/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $30.93 | General |
| 09/20/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Diabetes Care | ||||||
| 06/08/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Diabetes | ||||||
| 05/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: Diabetes | ||||||
| 04/29/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $30.33 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 04/16/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Diabetes | ||||||
| 03/13/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $14.29 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 02/03/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $13.86 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 01/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.98 | General |
| Category: Diabetes | ||||||
| 01/24/2024 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 01/12/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 01/10/2024 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Biological) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/19/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $33.10 | General |
| Category: Diabetes | ||||||
| 11/30/2023 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: Endogenous Testosterone Replacement Therapy | ||||||
| 11/09/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Diabetes | ||||||
| 11/06/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Diabetes Care | ||||||
| 10/30/2023 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Endocrinology | ||||||
| 10/23/2023 | Xeris Pharmaceuticals, Inc. | RECORLEV (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Adrenal steroidogenesis inhibitor | ||||||
| 10/20/2023 | RECORDATI_RARE_DISEASES_INC. | SIGNIFOR LAR (Drug), ISTURISA | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: ENDOCRINE AGENT | ||||||
| 10/16/2023 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: Endocrinology | ||||||
| 10/10/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 490 | 759 | $92,919 | $63,039 |
| 2022 | 8 | 651 | 1,153 | $136,265 | $79,126 |
| 2021 | 11 | 1,269 | 2,223 | $256,795 | $146,992 |
| 2020 | 11 | 1,127 | 1,976 | $219,980 | $127,292 |
Total Patients
3,537
Total Services
6,111
Medicare Billing
$416,449
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 157 | 358 | $35,800 | $24,648 | 68.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 104 | 104 | $19,864 | $11,676 | 58.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 64 | $9,728 | $7,312 | 75.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 90 | $9,900 | $7,269 | 73.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 51 | $7,344 | $5,281 | 71.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 53 | 65 | $3,900 | $2,812 | 72.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $2,730 | $2,079 | 76.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $3,653 | $1,961 | 53.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 175 | 512 | $51,200 | $32,309 | 63.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 158 | 160 | $32,000 | $18,996 | 59.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 124 | 244 | $19,520 | $8,363 | 42.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 87 | $10,440 | $6,086 | 58.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 67 | 67 | $10,720 | $5,824 | 54.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 47 | $6,580 | $4,274 | 65.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 25 | $4,375 | $2,787 | 63.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Facility | 2022 | 11 | 11 | $1,430 | $486.97 | 34.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 307 | 816 | $81,600 | $51,210 | 62.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 260 | 260 | $52,000 | $31,401 | 60.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 254 | 587 | $46,960 | $19,918 | 42.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 85 | 155 | $18,400 | $11,650 | 63.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 132 | 132 | $21,120 | $11,547 | 54.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 64 | 79 | $11,060 | $7,020 | 63.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 41 | 57 | $9,940 | $6,666 | 67.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 21 | 21 | $3,605 | $1,811 | 50.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 27 | 34 | $2,540 | $1,473 | 58.0% |
About Dr. Eric Reines, M.D
Dr. Eric Reines, M.D is a Infectious Disease healthcare provider based in Alexandria, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1700889342.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Reines, M.D has received a total of $7,714 in payments from pharmaceutical and medical device companies, with $362.34 received in 2024. These payments were reported across 460 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($7,500).
As a Medicare-enrolled provider, Reines has provided services to 3,537 Medicare beneficiaries, totaling 6,111 services with total Medicare billing of $416,449. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Alexandria, VA
- Active Since 05/27/2005
- Last Updated 01/28/2015
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1700889342
Products in Payments
- Korlym (Drug) $680.47
- JARDIANCE (Drug) $425.67
- Synthroid (Drug) $304.41
- TRIUMEQ (Drug) $286.46
- JANUVIA (Drug) $283.09
- SYNTHROID (Drug) $270.88
- Ozempic (Drug) $261.39
- Victoza (Drug) $216.01
- BAQSIMI (Drug) $204.20
- DOVATO (Drug) $191.86
- UNITHROID (Drug) $186.95
- TRULICITY (Drug) $182.75
- Omnipod (Device) $174.99
- PREZCOBIX (Drug) $157.67
- FARXIGA (Drug) $146.57
- GVOKE PFS (Drug) $146.50
- HUMULIN (Drug) $138.52
- ZERBAXA (Drug) $123.08
- ISENTRESS (Drug) $122.67
- Vascepa (Drug) $103.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Alexandria
Dr. Giorgos Hadjivassiliou, Mbbs, MBBS
Infectious Disease — Payments: $270.58
Infectious Disease $270.58
Imtiaz Choudhary, Md, MD
Infectious Disease — Payments: $57.28
Infectious Disease $57.28
Dr. Lisa Kaplowitz, Md, MD
Infectious Disease
Infectious Disease
David Frucht, Md, MD
Infectious Disease
Infectious Disease